SAB Biotherapeutics, Inc. (SABS)
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$12.8M
- Net margin
- —
Little or no net debt.
- Total debt
- $5.1M
- Cash
- $8.3M
- Debt / equity
- 0.02
Comfortably covers what is due within a year.
- Current assets
- $107.9M
- Current liabilities
- $11.7M
- Current ratio
- 9.22
Consumes cash and must keep raising it.
- Operating cash flow
- -$68.2M
- Free cash flow
- -$72.7M
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 79.8M
- Share growth (1y)
- 758.1%
- Cash runway
- 1 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
SABS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| SG&A Expense | 7.21 M | 6.60 M | 5.04 M | 3.71 M | 2.73 M | — |
| R&D Expense | 16.17 M | 13.40 M | 10.73 M | 8.97 M | 7.00 M | — |
| Operating Expenses | 23.38 M | 20.00 M | 15.77 M | 12.68 M | 9.73 M | — |
| Operating Income | -23.38 M | -20.00 M | -15.77 M | -12.68 M | -9.73 M | — |
| Pretax Income | -22.49 M | -18.87 M | -16.86 M | 45.45 M | -10.11 M | — |
| Tax Provision | — | — | — | — | — | — |
| Net Income | -22.49 M | -18.87 M | -16.86 M | 45.45 M | -10.11 M | — |
| EPS (Basic) | -0.28 | -0.35 | — | 0.50 | -1.09 | -0.56 |
| EPS (Diluted) | -0.28 | -0.35 | — | -0.21 | -1.09 | -0.56 |
| Shares Outstanding | 79.75 M | 53.56 M | — | 10.66 M | 9.29 M | 9.29 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.